307 related articles for article (PubMed ID: 28933312)
21. Expression analysis of Akirin-2, NFκB-p65 and β-catenin proteins in imatinib resistance of chronic myeloid leukemia.
Karabay AZ; Koc A; Ozkan T; Hekmatshoar Y; Altinok Gunes B; Sunguroglu A; Buyukbingol Z; Atalay A; Aktan F
Hematology; 2018 Dec; 23(10):765-770. PubMed ID: 29945498
[TBL] [Abstract][Full Text] [Related]
22. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F
Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609
[TBL] [Abstract][Full Text] [Related]
23. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies.
Jiang X; Zhao Y; Smith C; Gasparetto M; Turhan A; Eaves A; Eaves C
Leukemia; 2007 May; 21(5):926-35. PubMed ID: 17330101
[TBL] [Abstract][Full Text] [Related]
24. Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells.
Kuntz EM; Baquero P; Michie AM; Dunn K; Tardito S; Holyoake TL; Helgason GV; Gottlieb E
Nat Med; 2017 Oct; 23(10):1234-1240. PubMed ID: 28920959
[TBL] [Abstract][Full Text] [Related]
25. Modulating the Growth and Imatinib Sensitivity of Chronic Myeloid Leukemia Stem/Progenitor Cells with Pullulan/MicroRNA Nanoparticles In Vitro.
Ma W; Liu J; Xie J; Zhang X; Zhou H; Yao H; Zhang W; Guo D; Zhu L; Xiao L; Wu D; Xu H; Chen S; Zhao Y
J Biomed Nanotechnol; 2015 Nov; 11(11):1961-74. PubMed ID: 26554155
[TBL] [Abstract][Full Text] [Related]
26. Gas6/AXL Signaling Regulates Self-Renewal of Chronic Myelogenous Leukemia Stem Cells by Stabilizing β-Catenin.
Jin Y; Nie D; Li J; Du X; Lu Y; Li Y; Liu C; Zhou J; Pan J
Clin Cancer Res; 2017 Jun; 23(11):2842-2855. PubMed ID: 27852702
[No Abstract] [Full Text] [Related]
27. A conserved ZFX/WNT3 axis modulates the growth and imatinib response of chronic myeloid leukemia stem/progenitor cells.
Zhang X; Wang Y; Lu J; Xiao L; Chen H; Li Q; Li YY; Xu P; Ruan C; Zhou H; Zhao Y
Cell Mol Biol Lett; 2023 Oct; 28(1):83. PubMed ID: 37864206
[TBL] [Abstract][Full Text] [Related]
28. Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia.
Jin B; Wang C; Li J; Du X; Ding K; Pan J
Clin Cancer Res; 2017 Feb; 23(3):789-803. PubMed ID: 27492973
[TBL] [Abstract][Full Text] [Related]
29. The Culture Repopulation Ability (CRA) Assay and Incubation in Low Oxygen to Test Antileukemic Drugs on Imatinib-Resistant CML Stem-Like Cells.
Cheloni G; Tanturli M
Methods Mol Biol; 2016; 1465():73-85. PubMed ID: 27581140
[TBL] [Abstract][Full Text] [Related]
30. Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate.
Jiang X; Forrest D; Nicolini F; Turhan A; Guilhot J; Yip C; Holyoake T; Jorgensen H; Lambie K; Saw KM; Pang E; Vukovic R; Lehn P; Ringrose A; Yu M; Brinkman RR; Smith C; Eaves A; Eaves C
Blood; 2010 Sep; 116(12):2112-21. PubMed ID: 20574046
[TBL] [Abstract][Full Text] [Related]
31. SRSF1 mediates cytokine-induced impaired imatinib sensitivity in chronic myeloid leukemia.
Sinnakannu JR; Lee KL; Cheng S; Li J; Yu M; Tan SP; Ong CCH; Li H; Than H; Anczuków-Camarda O; Krainer AR; Roca X; Rozen SG; Iqbal J; Yang H; Chuah C; Ong ST
Leukemia; 2020 Jul; 34(7):1787-1798. PubMed ID: 32051529
[TBL] [Abstract][Full Text] [Related]
32. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J
J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437
[TBL] [Abstract][Full Text] [Related]
33. Hypoxia selects for a quiescent, CML stem/leukemia initiating-like population dependent on CBP/catenin transcription.
Kida A; Kahn M
Curr Mol Pharmacol; 2013 Nov; 6(3):204-10. PubMed ID: 24720539
[TBL] [Abstract][Full Text] [Related]
34. The β-catenin/CBP-antagonist ICG-001 inhibits pediatric glioma tumorigenicity in a Wnt-independent manner.
Wiese M; Walther N; Diederichs C; Schill F; Monecke S; Salinas G; Sturm D; Pfister SM; Dressel R; Johnsen SA; Kramm CM
Oncotarget; 2017 Apr; 8(16):27300-27313. PubMed ID: 28460484
[TBL] [Abstract][Full Text] [Related]
35. microRNA-199a/b-5p enhance imatinib efficacy via repressing WNT2 signaling-mediated protective autophagy in imatinib-resistant chronic myeloid leukemia cells.
Chen PH; Liu AJ; Ho KH; Chiu YT; Anne Lin ZH; Lee YT; Shih CM; Chen KC
Chem Biol Interact; 2018 Aug; 291():144-151. PubMed ID: 29890129
[TBL] [Abstract][Full Text] [Related]
36. Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells.
Trinh A; Khamari R; Fovez Q; Mahon FX; Turcq B; Bouscary D; Maboudou P; Joncquel M; Coiteux V; Germain N; Laine W; Dekiouk S; Jean-Pierre S; Maguer-Satta V; Ghesquiere B; Idziorek T; Quesnel B; Kluza J; Marchetti P
Mol Metab; 2022 Jan; 55():101410. PubMed ID: 34863941
[TBL] [Abstract][Full Text] [Related]
37. Targeting the Extracellular Signal-Regulated Kinase 5 Pathway to Suppress Human Chronic Myeloid Leukemia Stem Cells.
Tusa I; Cheloni G; Poteti M; Gozzini A; DeSouza NH; Shan Y; Deng X; Gray NS; Li S; Rovida E; Dello Sbarba P
Stem Cell Reports; 2018 Oct; 11(4):929-943. PubMed ID: 30245209
[TBL] [Abstract][Full Text] [Related]
38. Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines.
Wang Q; Ding W; Ding Y; Ma J; Qian Z; Shao J; Li Y
Oncotarget; 2017 Jun; 8(23):37594-37604. PubMed ID: 28410239
[TBL] [Abstract][Full Text] [Related]
39. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.
Hu Y; Chen Y; Douglas L; Li S
Leukemia; 2009 Jan; 23(1):109-16. PubMed ID: 18818703
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of CREB binding protein-beta-catenin signaling down regulates CD133 expression and activates PP2A-PTEN signaling in tumor initiating liver cancer cells.
Tang Y; Berlind J; Mavila N
Cell Commun Signal; 2018 Mar; 16(1):9. PubMed ID: 29530069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]